Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Metastatic Cancer|HER2-positive Breast Cancer|HER2-positive Gastric Cancer|HER-2 Protein Overexpression|Esophageal Cancer|Ovarian Cancer|Endometrium Cancer|Bladder Cancer|Pancreatic Cancer|Colorectal Cancer|Non Small Cell Lung Cancer|EGF-R Positive Non-Small Cell Lung Cancer|Head and Neck Squamous Cell Carcinoma|Triple Negative Breast Cancer|Cervical Cancer|Sarcoma
Interventions: BIOLOGICAL: SNK01|DRUG: Trastuzumab|DRUG: Cetuximab
Sponsor: NKGen Biotech, Inc.